

**Ref: STEX/OUTCOME/2023-24**

**Date: 08.08.2023**

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001  BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051  NSE Code: MEDICAMEQ
---	--

**Sub. : Outcome of Board Meeting**

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023, were approved by the Board of Directors of the Company at its meeting held today at 12.30 P.M. and concluded at 02.15 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2023; and
- Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter.

We request you to take the same on record

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2023, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

R. B. Bhatnagar



8	Other Comprehensive Income	Profit & Loss	-
9	Total Comprehensive Income net of Tax		441.70
10	Net Profit /Loss attributable to		
	a) Controlling Interest		
	b) Non-controlling Interest		
10	Paid up equity share capital (Rs. 10/- per share)		1,265.11
11	Earning Per Share (Rs.)		
	Basic		3.49
	Diluted		3.49

#### NOTES :

- The Un-audited financial results for the quarter ended have been reviewed by the Auditors.
- This statement has been prepared in accordance with the Companies (Indian Accounting) Rules, 2015 and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 20.
- The results are not comparable on quarterly or yearly basis as company is regularly incurring losses, hence segment reporting is not applicable.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi  
Dated : 08.08.2023

Page

No. 02

404.6						
50	358.56	1,500.20	394.70	376.87	358.56	1,472.85
			417.72 (23.02)	388.97 (12.10)	358.56 -	1,484.41 (11.56)
1,265.11						
3.2						
3.21	1,221.66	1,265.11	1,265.11	1,265.11	1,221.66	1,265.11
5	2.94	12.04	3.12	3.03	2.94	11.82
5	2.94	12.04	3.12	3.03	2.94	11.82

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*  
(Rahul Bishnoi)  
Chairman

# RAI QIMAT & ASSOCIATES

## CHARTERED ACCOUNTANTS



Independent Auditor's Limited Review Report on unaudited standalone financial results of Medicamen Biotech Limited for the quarter ended June 30, 2023, pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of  
Medicamen Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medicamen Biotech Limited ('the Company') for the quarter ended June 30, 2023 ('the Statement') attached herewith, being prepared and submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').
2. This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant Rules issued thereunder and other accounting principles generally accepted in India, read with the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to

and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in all material respects in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting

Standards, prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant Rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RAI QIMAT & ASSOCIATES  
Chartered Accountants



Independent Auditor's limited review report on unaudited consolidated financial results of Medicamen Biotech Limited for the quarter ended June 30, 2023 pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of  
Medicamen Biotech Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Medicamen Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2023 (the 'Statement') attached herewith, being prepared and submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended thereafter ('the Listing Regulations').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("the ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing, and consequently, does not enable us to obtain assurance that we would have known of any significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CKN/CFU/CINM/4472019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial results of the following entities:

**Subsidiaries**

Opal Pharmaceutical Pty Ltd  
Medicamen Life Sciences Private Limited


5. Based on our review conducted and procedures performed as stated in paragraph 3 above and paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principle laid down in the aforesaid Indian Accounting Standard ('Ind AS') prescribed under Section 133 the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to

be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects total revenue of Rs. 143.97 and, total net (loss) after tax of Rs. 0.47 lakhs and total comprehensive loss of Rs. 0.47 lakhs for the quarter ended June 30, 2023 as considered in the Statement. This interim financial information have been furnished to us by the management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion on the statement is not modified in respect of matter stated in paragraph above.

**For Rai Qimat & Associates**  
**Chartered Accountants**

  
Qimat Rai Garg  
Partner

(Membership Number: 080857)

UDIN: 23080857BGYGVH9681

Place: Gurugram

Date: 08.08.2023